NCT07482774 2026-03-19
TME-ESCC
Nanjing Medical University
Not yet recruiting
Clinical Trials
46 trialsNCT07463573 2026-03-11
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07452601 2026-03-05
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT07405151 2026-02-12
MK-3475-06F
Merck Sharp & Dohme LLC
Phase 1/2 Not yet recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06828588 2026-01-29
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07376876 2026-01-29
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT07353541 2026-01-20
PKU-ESCC-EF
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT07343869 2026-01-15
FEO
Société Française d'Endoscopie Digestive
Not yet recruiting
NCT07272291 2025-12-09
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07244978 2025-12-02
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07203898 2025-10-02
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
Beijing Immupeutics Medicine Technology Limited
Phase 1 Not yet recruiting
NCT07177794 2025-09-17
EC-CRT-008
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07152535 2025-09-03
PKU-ESCC
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT07128693 2025-08-19
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06971848 2025-07-11
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT07049185 2025-07-03
QICE-ESCC
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT06861894 2025-05-15
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06889402 2025-03-21
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not yet recruiting
NCT06861777 2025-03-11
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Not yet recruiting
NCT06746961 2024-12-24
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Not yet recruiting
NCT06703047 2024-11-25
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06588335 2024-09-19
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT06598917 2024-09-19
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
China Medical University Hospital
Phase 2 Not yet recruiting
NCT06508229 2024-07-18
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
Harbin Medical University
Phase 2 Not yet recruiting
NCT06501664 2024-07-15
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06491134 2024-07-08
Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 1 Not yet recruiting
NCT06487702 2024-07-05
A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06468644 2024-06-21
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06468670 2024-06-21
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06426797 2024-05-23
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06252974 2024-04-29
Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data
RenJi Hospital
Not yet recruiting
NCT06388135 2024-04-29
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Xijing Hospital
Phase 4 Not yet recruiting
NCT06178211 2023-12-20
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06152978 2023-12-01
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06055166 2023-09-26
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Chongqing University Cancer Hospital
Phase 2 Not yet recruiting
NCT06010212 2023-08-24
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Not yet recruiting
NCT05896787 2023-06-09
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT05791136 2023-03-30
TREE
The Central Hospital of Lishui City
Phase 2 Not yet recruiting
NCT05759325 2023-03-08
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
Guangzhou Institute of Respiratory Disease
Not yet recruiting
NCT05732662 2023-02-17
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
The First People's Hospital of Changzhou
Phase 2 Not yet recruiting
NCT05244798 2022-10-25
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Not yet recruiting
NCT05420480 2022-06-21
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
Shanghai Zhongshan Hospital
Phase NA Not yet recruiting
NCT02490735 2015-07-07
CIK in Treating Patients With Esophageal Cancer
The First People's Hospital of Changzhou
Phase 2 Not yet recruiting